CBO-003

N/A

Report date: 2025/11/21 17:29:28

Base Information

Drug NameCBO-003

Drug Alias NameCBO-003CBO003

ClassificationDiagnostic agent (In vivo) > Radionuclide Imaging agentBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody fragment > Single-domain antibody (Nanobody)Biologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody diagnostics +[5]

Mechanisms of ActionAnti-CD276

TargetsCD276 antigen

Therapy Area/IndicationsGlioblastoma

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritorySwitzerland

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesCIS Biopharma AG

China Registration ClassN/A

Develop Information

Active CompaniesCIS Biopharma AG

Inactive CompaniesN/A

Active IndicationsGlioblastoma

Inactive IndicationsN/A

Other Information

ATC CodeN/A